Jump to content

Drospirenone/estetrol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Whywhenwhohow (talk | contribs) at 06:51, 4 January 2021 (update infobox, description, links, sort). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Drospirenone/estetrol
Combination of
EstetrolEstrogen
DrospirenoneProgestogen
Clinical data
Other namesE4/DRSP; FSN-013
AHFS/Drugs.comMonograph
Routes of
administration
By mouth
ATC code
Identifiers
ChemSpider
  • None

Estetrol/drospirenone (E4/DRSP; developmental code name FSN-013) is a combination of estetrol, an estrogen, and drospirenone, a progestin, which is under development by Estetra S.A. as a combined oral contraceptive for the prevention of pregnancy in women.[1] It contains 15 mg estetrol and 3 mg drospirenone.[2] As of 2018, it is in phase III clinical trials for this indication.[1]

E4/DRSP has a much lower impact on liver protein synthesis, including of sex hormone-binding globulin, angiotensinogen, and coagulation factors, than does ethinylestradiol/drospirenone.[3]

See also

References

  1. ^ a b http://adisinsight.springer.com/drugs/800034634
  2. ^ https://investors.mithra.com/wp-content/uploads/2018/08/2018-08-08-Estelle-Phase-III-EU-RU-en.pdf
  3. ^ Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G (October 2017). "Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis". Expert Rev Clin Pharmacol. 10 (10): 1129–1144. doi:10.1080/17512433.2017.1356718. PMID 28712325. S2CID 205931204.